Pharvaris Announces Annual Meeting of Shareholders
June 14 2022 - 8:10AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
HAE attacks, building on its deep-seated roots in hereditary
angioedema (HAE), today announced the annual general meeting of
shareholders will take place on Wednesday, June 29, 2022, at 16:00
CEST (10:00 a.m. EDT).
All relevant documents and information relating to the annual
general meeting, including the notice and agenda for the annual
general meeting, are or will be made available in the “Investors”
section of Pharvaris’ website under “Events & Presentations”.
The documents will also be made available on the SEC’s website at
www.sec.gov. Shareholders who wish to attend the meeting should
register as described in the notice and agenda for the annual
general meeting.
About PharvarisPharvaris is a clinical-stage
company developing novel, oral bradykinin-B2-receptor antagonists
to treat and prevent HAE attacks, building on its deep-seated roots
in HAE. By directly targeting this clinically proven therapeutic
target with novel small molecules, the Pharvaris team aspires to
offer people with all sub-types of HAE more effective and
convenient alternatives to treat attacks, both on-demand and
prophylactically. The company brings together the best talent in
the industry with deep expertise in rare diseases and HAE. For more
information, visit https://pharvaris.com/.
Contact:Maryann CiminoDirector of Corporate
Relationsmaryann.cimino@pharvaris.com +1-617-710-7305
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Apr 2023 to Apr 2024